Relation between triketone structure, generation of reactive oxygen species, and selective toxicity of the diabetogenic agent alloxan

Antioxidants and Redox Signaling

Volumn 10, Issue 4, 2008, Pages 691-699

  Elsner, Matthias ^a   Gurgul Convey, Ewa ^a   Lenzen, Sigurd ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOXAN; CATALASE; CYSTEINE; DITHIOL DERIVATIVE; GLUCOSE TRANSPORTER 2; GLUTATHIONE; KETONE; NINHYDRIN; REACTIVE OXYGEN METABOLITE; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRUCTURE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DIABETOGENESIS; ENZYME PHOSPHORYLATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALLOXAN; ANIMALS; CELLS, CULTURED; GLUCOSE TRANSPORTER TYPE 2; GLUTATHIONE; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MOLECULAR STRUCTURE; NINHYDRIN; OXYGEN; PHOSPHORYLATION; RATS; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP; TOLUENE;

EID: 38949135227     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1816     Document Type: Article

References (31)

1. Abderhalden R. Über die Einwirkung von Ninhydrin, Alloxan und Isatin auf Aminosäuren und Polypeptide. Zeitschr Physiol Chem 252: 81-94, 1938.
2. Bennett RA and Pegg AE. Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res 41: 2786-2790, 1981.
3. Brömme HJ, Mörke W, Weinandy R, Peschke D, and Peschke E. Formation of compound 305 requires the simultaneous generation of both alloxan and GSH radicals. Horm Metab Res 34: 62-66, 2002.
4. Brömme HJ, Weinandy R, and Peschke E. Influence of oxygen concentration on redox cycling of alloxan and dialuric acid. Horm Metab Res 37: 729-733, 2005.
5. Brückmann G and Wertheimer E. Alloxan studies: the action of alloxan homologues and related compounds. J Biol Chem 168: 241-256, 1947.
6. Elsner M, Guldbakke B, Tiedge M, Munday R, and Lenzen S. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia 43: 1528-1533, 2000.
7. Elsner M, Gurgul-Convey E, and Lenzen S. Relative importance of cellular uptake and reactive oxygen species for the toxicity of alloxan and dialuric acid to insulin-producing cells. Free Radic Biol Med 41: 825-834, 2006.
8. Elsner M, Tiedge M, Guldbakke B, Munday R, and Lenzen S. Importance of the GLUT2 glucose transporter for pancreatic beta cell toxicity of alloxan. Diabetologia 45: 1542-1549, 2002.
9. Elsner M, Tiedge M, and Lenzen S. Mechanism underlying resistance of human pancreatic beta cells against toxicity of streptozotocin and alloxan. Diabetologia 46: 1713-1714, 2003.
10. Gazdar AF, Chick WL, Oie HK, Sims HL, King DL, Weir GC, and Lauris V. Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. Proc Natl Acad Sci U S A 77: 3519-3523, 1980.
11. Green MH, Lowe JE, Petit-Frere C, Karran P, Hall J, and Kataoka H. Properties of N-methyl-N-nitrosourea-resistant, Mex- derivatives of an SV40-immortalized human fibroblast cell line. Carcinogenesis 10: 893-898, 1989.
12. Hidy PH. Structural requirements for diabetogenic action in alloxan and related compounds. J Biol Chem 163: 307-311, 1946.
13. Konrad RJ and Kudlow JE. The role of O-linked protein glycosylation in beta-cell dysfunction. Int J Mol Med 10: 535-539, 2002.
14. Ledoux SP, Woodley SE, Patton NJ, and Wilson GL. Mechanisms of nitrosourea-induced beta-cell damage: alterations in DNA. Diabetes 35: 866-872, 1986.
15. Lenzen S. Insulin secretion by isolated perfused rat and mouse pancreas. Am J Physiol 236: E391-E400, 1979.
16. Lenzen S, Brand FH, and Panten U. Structural requirements of alloxan and ninhydrin for glucokinase inhibition and of glucose for protection against inhibition. Br J Pharmacol 95: 851-859, 1988.
17. Lenzen S, Freytag S, Panten U, Flatt PR, and Bailey CJ. Alloxan and ninhydrin inhibition of hexokinase from pancreatic islets and tumoural insulin-secreting cells. Pharmacol Toxicol 66: 157-162, 1990.
18. Lenzen S and Munday R. Thiol-group reactivity, hydrophilicity and stability of alloxan, its reduction products and its N-methyl derivatives and a comparison with ninhydrin. Biochem Pharmacol 42: 1385-1391, 1991.
19. Lenzen S, Tiedge M, and Panten U. Glucokinase in pancreatic B-cells and its inhibition by alloxan. Acta Endocrinol (Copenh) 115: 21-29, 1987.
20. McCaldin DJ. The chemistry of ninhydrin. Chem Rev 60: 39-51, 1960.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
22. Munday R. Dialuric acid autoxidation: effects of transition metals on the reaction rate and on the generation of "active oxygen" species. Biochem Pharmacol 37: 409-413, 1988.
23. Munday R, Ludwig K, and Lenzen S. The relationship between the physicochemical properties and the biological effects of alloxan and several N-alkyl substituted alloxan derivatives. J Endocrinol 139: 153-163, 1993.
24. Munday R and Winterbourn CC. Reduced glutathione in combination with superoxide dismutase as an important biological antioxidant defence mechanism. Biochem Pharmacol 38: 4349-4352, 1989.
25. Murata M, Takahashi A, Saito I, and Kawanishi S. Site-specific DNA methylation and apoptosis: induction by diabetogenic streptozotocin. Biochem Pharmacol 57: 881-887, 1999.
26. Prota G and Ponsiglione E. On the reaction of ninhydrin with cysteine and analogues: a revision. Tetrahedron 29: 4271-4274, 1973.
27. Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 22: 485-518, 1970.
28. Schönberg A and Singer A. Die Chemie des Ninhydrins und anderer cyclischer 1,2,3-Tricarbonylverbindungen. Tetrahedron 34: 1285-1300, 1978.
29. Tiedge M, Lortz S, Drinkgern J, and Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46: 1733-1742, 1997.
30. Tiedge M, Lortz S, Munday R, and Lenzen S. Complementary action of antioxidant enzymes in the protection of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species. Diabetes 47: 1578-1585, 1998.
31. Winterbourn CC and Munday R. Glutathione-mediated redox cycling of alloxan: mechanisms of superoxide dismutase inhibition and of metal-catalyzed OH. formation. Biochem Pharmacol 38: 271-277, 1989.